These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 22508373)

  • 1. A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
    Sunakawa Y; Fujita K; Ichikawa W; Ishida H; Yamashita K; Araki K; Miwa K; Kawara K; Akiyama Y; Yamamoto W; Nagashima F; Saji S; Sasaki Y
    Oncology; 2012; 82(4):242-8. PubMed ID: 22508373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer].
    Song Y; Li WW; Huang J
    Zhonghua Zhong Liu Za Zhi; 2017 May; 39(5):380-383. PubMed ID: 28535657
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.
    Yamashita K; Nagashima F; Fujita K; Yamamoto W; Endo H; Miya T; Narabayashi M; Kawara K; Akiyama Y; Ando Y; Ando M; Sasaki Y
    Jpn J Clin Oncol; 2011 Feb; 41(2):204-9. PubMed ID: 20965940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
    Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
    J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1 genotype and physical background is feasible in Japanese patients with advanced colorectal cancer.
    Ishida H; Fujita K; Akiyama Y; Sunakawa Y; Yamashita K; Mizuno K; Miwa K; Kawara K; Ichikawa W; Ando Y; Saji S; Sasaki Y
    Jpn J Clin Oncol; 2011 May; 41(5):617-23. PubMed ID: 21310730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule.
    Masi G; Allegrini G; Cupini S; Marcucci L; Cerri E; Brunetti I; Fontana E; Ricci S; Andreuccetti M; Falcone A
    Ann Oncol; 2004 Dec; 15(12):1766-72. PubMed ID: 15550581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of primary treatment with 5-FU, oxaliplatin, irinotecan, levofolinate, and panitumumab combination chemotherapy in patients with advanced/recurrent colorectal cancer involving the wild-type RAS gene: the JACCRO CC-14 study.
    Satake H; Tsuji A; Nakamura M; Ogawa M; Kotake T; Hatachi Y; Yasui H; Takagane A; Okita Y; Nakamura K; Onikubo T; Takeuchi M; Fujii M
    Int J Clin Oncol; 2018 Jun; 23(3):490-496. PubMed ID: 29464396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis on safety and preliminary efficacy of dose-modified regimen of 5-fluorouracil plus oxaliplatin and irinotecan (FOLFOXIRI) in advanced colorectal cancer].
    Cai Y; Deng R; Hu H; Zhang J; Ling J; Wu Z; Yang L; Li J; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Sep; 21(9):1045-1050. PubMed ID: 30269326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
    Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
    Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
    Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
    Marcuello E; Páez D; Paré L; Salazar J; Sebio A; del Rio E; Baiget M
    Br J Cancer; 2011 Jun; 105(1):53-7. PubMed ID: 21654688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K
    Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
    Cals L; Rixe O; François E; Favre R; Merad L; Deplanque G; Laadem A; Juin P; Bereder JM; Bernardini D; Herait P
    Ann Oncol; 2004 Jul; 15(7):1018-24. PubMed ID: 15205194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
    Sasaki Y; Hamaguchi T; Arai T; Goto A; Ura T; Muro K; Yamada Y; Shirao K; Shimada Y
    Anticancer Res; 2014 Apr; 34(4):2029-34. PubMed ID: 24692743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
    Sunakawa Y; Ichikawa W; Fujita K; Nagashima F; Ishida H; Yamashita K; Mizuno K; Miwa K; Kawara K; Akiyama Y; Araki K; Yamamoto W; Miya T; Narabayashi M; Ando Y; Hirose T; Saji S; Sasaki Y
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):279-84. PubMed ID: 20957480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
    Cao W; Yang W; Lou G; Jiang J; Geng M; Xi W; Li H; Ma T; Jin Y
    Anticancer Drugs; 2009 Apr; 20(4):287-93. PubMed ID: 19177020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
    Oki E; Kato T; Bando H; Yoshino T; Muro K; Taniguchi H; Kagawa Y; Yamazaki K; Yamaguchi T; Tsuji A; Iwamoto S; Nakayama G; Emi Y; Touyama T; Nakamura M; Kotaka M; Sakisaka H; Yamanaka T; Kanazawa A
    Clin Colorectal Cancer; 2018 Jun; 17(2):147-155. PubMed ID: 29530335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
    Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: a Korean single-center experience.
    Park SH; Sung JY; Han SH; Baek JH; Oh JH; Bang SM; Cho EK; Shin DB; Lee JH
    Jpn J Clin Oncol; 2005 Sep; 35(9):531-5. PubMed ID: 16027146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.